AM-Pharma
Manufacturing · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Stadsplateau 6, Utrecht, Utrecht, 3521, ...Phone Number
+31 302289222Website
www.am-pharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About AM-Pharma
AM-Pharma, founded in 2001 and headquartered in Utrecht, the Netherlands, is a late-stage clinical development and pharmaceutical manufacturing company specializing in sepsis-associated acute kidney injury.Explore more
AM-Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AM-Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if AM-Pharma had a recent Job posting/layoffs
AM-Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if AM-Pharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at AM-Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if AM-Pharma is spiking on competitors!
Product Launch: Get notified when AM-Pharma launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on AM-Pharma recently announced quarterly report
Funding: Get notified immidiatlly once AM-Pharma has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
AM-Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AM-Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AM-Pharma.
AM-Pharma financials insights
Gather financial insights about AM-Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2001
Series A
$781K
2007
Series C
$3M
2011
Series D
$34.5M
2014
Series E
$14.4M
2015
Private Equity
$87.5M
2020
Series F
$185M
AM-Pharma Tech Stack
A closer look at the technologies used by AM-Pharma
See more technologies
Most Recent Scoops
Event
Events
Lateral Move
Executive Move
Board of Directors
New Hire
Executive Move
Left Company
Executive Move
New Hire
Executive Move
AM-Pharma News & Media
AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage
UTRECHT, The Netherlands--(BUSINESS WIRE)--AM-Pharma B.V. today announced that the first patients have been treated in a Phase 2 clinical study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage (CSA-RD). With over 2 million open heart surgeries1 performed worldwide every year, CSA-RD represents a critical surgical complication for which there is no specific pharmacological therapy. CSA-RDAM-Pharma Announces Positive Clinical Data From Phase 1b Study Evaluating Ilofotase Alfa in Hypophosphatasia Patients
UTRECHT, The Netherlands--(BUSINESS WIRE)-- #AMPharma--AM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia (HPP) patients. HPP is an inherited metabolic disease, characterized by low activity of tissue non-specific alkaline phosphatase (TNAP), caused by mutations at the ALPL gene. This low activity leads to accumulatAM-Pharma Announces Updated Clinical Development Strategy
UTRECHT, The Netherlands--(BUSINESS WIRE)-- #AMPHARMA--AM-Pharma B.V. today announced an updated clinical development strategy to evaluate ilofotase alfa in two indications. The company’s proprietary compound ilofotase alfa is a recombinant alkaline phosphatase with an extensive clinical record and proven safety profile. Based on the significant improvements in Major Adverse Kidney Events by day 90 (MAKE90) observed in the company’s Phase 2 and Phase 3 studies with ilofotase alfa in sepsis-assocAM-Pharma to Present Data From Phase 3 REVIVAL Study at Upcoming Scientific Conferences
UTRECHT, The Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Professor Peter Pickkers, M.D., Ph.D., principal investigator of the Phase 3 REVIVAL study, will present data from the study at two upcoming scientific conferences. The data from 650 patients with Sepsis-associated Acute Kidney Injury (SA-AKI), will be featured in presentations at the 42nd International Symposium on Intensive Care &
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AM-Pharma
Sign Up For FreeTo access detailed company insights
AM-Pharma, founded in 2001 and headquartered in Utrecht, the Netherlands, is a late-stage clinical development and pharmaceutical manufacturing company specializing in sepsis-associated acute kidney injury.... Read More
